Innovation in cellular immunotherapy: how to reach more patients?

CELL AND GENE THERAPY INSIGHTS

Innovation in cellular immunotherapy: how to reach more patients?

August 2024
Innovation in cellular immunotherapy: how to reach more patients?
Download PDF

Foreword

Cellular immunotherapy: beyond hemalignancies

Cellular immunotherapy: beyond hemalignancies

Nina Bauer
8 September
Read

Expert Insight

Patient-specific factors that could influence gene therapy outcomes in sickle cell disease

Patient-specific factors that could influence gene therapy outcomes in sickle cell disease

Abdulrahman Alsultan, Jaap Jan Boelens
1 September
Read

Innovator Insight

Enhancing CAR-T cell generation: optimizing non-viral engineering of resting T cells for improved cancer immunotherapy

Enhancing CAR-T cell generation: optimizing non-viral engineering of resting T cells for improved cancer immunotherapy

Akshaya Chandrasekaran
11 September
Read

Regulatory perspective

Navigating the challenges of developing delivery devices for cell and gene therapy products in Europe

Navigating the challenges of developing delivery devices for cell and gene therapy products in Europe

Eamonn McGowran, Patrick Ginty
26 August
Read

Viewpoint

Cellular immunotherapy—a matter of delivery?

Cellular immunotherapy—a matter of delivery?

Nina Bauer
4 September
Read
A pathway forward for CAR-NK cell therapy

A pathway forward for CAR-NK cell therapy

Scott McComb
5 August
Read

Interview

Analyzing early successes, current challenges, and future opportunities in the in vivo cellular immunotherapy field

Analyzing early successes, current challenges, and future opportunities in the in vivo cellular immunotherapy field

Ye Zeng
8 August
Read
Following the data: lessons learned from the development of afami-cel

Following the data: lessons learned from the development of afami-cel

Jo Brewer
5 August
Read
Addressing autoimmune diseases with engineered MSCs

Addressing autoimmune diseases with engineered MSCs

Miguel Forte
13 June
Read
How will recent agency initiatives and likely future directions for regulatory CMC guidance impact the cellular immunotherapy space?

How will recent agency initiatives and likely future directions for regulatory CMC guidance impact the cellular immunotherapy space?

Adeyemi Afuwape
5 June
Read

Webinars

Large-scale manufacturing of allogeneic stem cell-derived NK cell therapies

Large-scale manufacturing of allogeneic stem cell-derived NK cell therapies

Monica Raimo, Jan Spanholtz
6 August
Watch
Understanding and leveraging cord blood bank capabilities and practices in cell therapy development

Understanding and leveraging cord blood bank capabilities and practices in cell therapy development

J Aho, A Conerty, S Shields et al.
15 August
Watch